vTv Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
VTVT$21.00-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations for the Years Ended and
Consolidated Statements of Operations
(in thousands, except per share and share data)
| Years Ending December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Revenue | $— | $1,017 | $— |
| Operating expenses: | |||
| Research and development | 17,861 | 11,546 | 13,595 |
| General and administrative | 14,947 | 13,651 | 11,907 |
| Total operating expenses | 32,808 | 25,197 | 25,502 |
| Operating loss | (32,808) | (24,180) | (25,502) |
| Other (expense) income, net | (109) | 160 | (1,497) |
| Other (expense) income – related party | (27) | (150) | 574 |
| Interest income | 1,870 | 1,565 | 472 |
| Interest expense | (6) | — | (13) |
| Loss before income taxes and noncontrolling interest | (31,080) | (22,605) | (25,966) |
| Income tax provision | — | 100 | — |
| Net loss before noncontrolling interest | (31,080) | (22,705) | (25,966) |
| Less: net loss attributable to noncontrolling interest | (4,106) | (4,243) | (5,716) |
| Net loss attributable to vTv Therapeutics Inc. | $(26,974) | $(18,462) | $(20,250) |
| Net loss attributable to vTv Therapeutics Inc. common shareholders | $(26,974) | $(18,462) | $(20,250) |
| Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted | $(3.20) | $(3.20) | $(9.71) |
| Weighted average number of vTv Therapeutics Inc. Class A common stock, basic and diluted | 8,423,632 | 5,771,052 | 2,084,973 |
Consolidated Statements of Changes in Redeemable Noncontrolling Interest and Stockholders’ Equity (Deficit)
(in thousands, except share data)
| Class A Common Stock · Class B Common Stock | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| RedeemableNoncontrollingInterest | Shares | Amount | Shares | Amount | AdditionalPaid-inCapital | Accumulated Deficit | Total vTv Therapeutics Inc Stockholders’ Equity (Deficit) | NoncontrollingInterest | Total Stockholders' Equity (Deficit) | |
| Balances at December 31, 2022 | $16,579 | 2,084,973 | $21 | 577,349 | $6 | $254,757 | $(265,524) | $(10,740) | $— | $(10,740) |
| Net loss | (5,716) | — | — | — | — | — | (20,250) | (20,250) | — | (20,250) |
| Share-based compensation | — | — | — | — | — | 1,578 | — | 1,578 | — | 1,578 |
| Change in redemption value of noncontrolling interest | (4,732) | — | — | — | — | — | 4,732 | 4,732 | — | 4,732 |
| Balances at December 31, 2023 | 6,131 | 2,084,973 | 21 | 577,349 | 6 | 256,335 | (281,042) | (24,680) | — | (24,680) |
| Net loss attributable to vTv Therapeutics Inc. | — | — | — | — | — | — | (18,462) | (18,462) | — | (18,462) |
| Net loss attributable to redeemable noncontrolling interest(*) | (1,085) | — | — | — | — | — | — | — | — | — |
| Change in redemption value of redeemable noncontrolling interest | 214 | — | — | — | — | — | (214) | (214) | — | (214) |
| Reclassification of redeemable noncontrolling interest to permanent equity (See Note 10) | (5,260) | — | — | — | — | — | — | — | 5,260 | 5,260 |
| Share-based compensation | — | — | — | — | — | 2,757 | — | 2,757 | — | 2,757 |
| Issuance of Class A common stock and pre-funded warrants, net offering costs | — | 347,884 | 3 | — | — | 50,332 | — | 50,335 | — | 50,335 |
| Issuance of Class A Common Stock under ATM offering | — | 179,400 | 2 | — | — | 2,461 | — | 2,463 | — | 2,463 |
| Net loss attributable to noncontrolling interest | — | — | — | — | — | — | — | — | (3,158) | (3,158) |
| Balances at December 31, 2024 | — | 2,612,257 | 26 | 577,349 | 6 | 311,885 | (299,718) | 12,199 | 2,102 | 14,301 |
| Net loss attributable to vTv Therapeutics Inc. | — | — | — | — | — | — | (26,974) | (26,974) | — | (26,974) |
| Issuance of common stock upon exercise of stock options | — | 1,336 | — | — | — | 16 | — | 16 | — | 16 |
| Shares withheld related to net share settlement of equity awards | — | 4,258 | — | — | — | (51) | — | (51) | — | (51) |
| Share-based compensation | — | — | — | — | — | 3,775 | — | 3,775 | — | 3,775 |
| Issuance of common shares and equity classified warrants, net of offering costs | — | 682,018 | 7 | — | — | 77,469 | — | 77,476 | — | 77,476 |
| Issuance of common stock - warrants exercised | — | 61,677 | — | — | — | — | — | — | — | — |
| Conversion of Class B Common Stock to Class A Common Stock | — | 577,108 | 6 | (577,108) | (6) | — | — | — | — | — |
| Reclassification of noncontrolling interest to additional paid-in capital | — | — | — | — | — | (2,004) | — | (2,004) | 2,004 | — |
| Net loss attributable to noncontrolling interest | — | — | — | — | — | — | — | — | (4,106) | (4,106) |
| Balances at December 31, 2025 | $— | 3,938,654 | $39 | 241 | $— | $391,090 | $(326,692) | $64,437 | $— | $64,437 |
| (*) Allocation of NCI net loss was a result from the reclassification to permanent equity on February 27, 2024 (See Note 10) | ||||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.